The HERA, the European Commission’s Health Emergency Preparedness and Response Authority, has signed a joint procurement framework contract with the Spanish company HIPRA for the supply of your protein vaccine against Covid-19. The Catalan company It is the only Spanish that has managed to develop, for the moment, a vaccine against Covid-19.
Fourteen Member States and countries participate in the joint procurement, which can purchase up to 250 million doses under the joint procurement. Given the new increase in cases in Europe, this agreement will quickly make HIPRA’s vaccine available to participating countries, as soon as the aforementioned vaccine has received a positive evaluation by the European Medicines Agency.
Stella Kyriakides, Commissioner for Health and Food Safety, has stated that, given the increase in Covid-19 infections in Europe, “we have to ensure maximum preparation for the autumn and winter months”.
[La vacuna española contra la Covid llegará en octubre como cuarta dosis]
The HIPRA vaccine adds one more option that complements the vaccine portfolio of the member states. “It is essential that vaccination and booster doses increase in the coming months. We are working tirelessly to ensure the availability of vaccines for all. This is our European Health Union in action: a Union that prepares ahead of time and is ready to act,” he said.
The joint procurement contract with HIPRA complements an already extensive portfolio of vaccines procured through the EU Vaccine Strategy, including contracts already signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, Moderna, Novavax, and Valneva.
Some have been achieved 4.2 billion doses under the EU Vaccine Strategy. This diversified portfolio of vaccines will ensure that Europe remains well prepared for vaccination against Covid-19, using vaccines that have been shown to be safe and effective. Participating countries could decide to donate the vaccines to low- and middle-income countries or redirect them to other European countries.
[La vacuna española contra la Covid es efectiva contra las subvariantes BA.4 y BA.5 según Hipra]
HIPRA’s bivalent recombinant protein vaccine, which is currently under continuous review by the European Medicines Agency, is being developed as a booster dose in previously immunized people aged 16 years and older.
HIPRA’s vaccine is stored at a refrigerated temperature of 2-8°C, facilitating storage and distribution in Europe and worldwide.
HIPRA’s Covid-19 vaccine is currently undergoing continuous review by the European Medicines Agency (EMA). If the vaccine receives a marketing authorization, the participating countries will be able to acquire it through the current framework contract.
Follow the topics that interest you